Literature DB >> 12132002

Rapid DOTS expansion in India.

G R Khatri1, Thomas R Frieden.   

Abstract

Since late 1998 the coverage of the DOTS strategy in India has been expanded rapidly. In both 2000 and 2001 the country probably accounted for more than half the global increase in the number of patients treated under DOTS and by early 2002 more than a million patients were being treated in this way in India. As a result, nearly 200 000 lives were saved. The lessons learnt relate to the importance of the following elements of the programme: (1) getting the science right and ensuring technical excellence; (2) building commitment and ensuring the provision of funds and flexibility in their utilization; (3) maintaining focus and priorities; (4) systematically appraising each area before starting service delivery; (5) ensuring an uninterrupted drug supply; (6) strengthening the established infrastructure and providing support for staff; (7) supporting the infrastructure required in urban areas; (8) ensuring full-time independent technical support and supervision, particularly during the initial phases of implementation; (9) monitoring intensively and giving timely feedback; and (10) continuous supervision. Tuberculosis (TB) control still faces major challenges in India. To reach its potential, the control programme needs to: continue to expand so as to cover the remaining half of the country, much of which has a weaker health infrastructure than the areas already covered; increase its reach in the areas already covered so that a greater proportion of patients is treated; ensure sustainability; improve the patient-friendliness of services; confront TB associated with human immunodeficiency virus (HIV) infection. It is expected that HIV will increase the number of TB cases by at least 10% and by a considerably higher percentage if HIV becomes much more widespread. India's experience shows that DOTS can achieve high case-detection and cure rates even with imperfect technology and often with an inadequate public health infrastructure. However, this can only happen if the delivery programme is appropriately designed and effectively managed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12132002      PMCID: PMC2567532     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  7 in total

1.  The impact of HIV/AIDS on the control of tuberculosis in India.

Authors:  B G Williams; R Granich; L S Chauhan; N S Dharmshaktu; C Dye
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-23       Impact factor: 11.205

2.  Five-years experiences of the Revised National Tuberculosis Control Programme in northern part of Kolkata, India.

Authors:  Sudipta Pandit; Atin Dey; Arunabha Datta Chaudhuri; Mita Saha; Amitava Sengupta; Sushmita Kundu; Sourin Bhuniya; Shib Singh
Journal:  Lung India       Date:  2009-10

3.  Scaling up global health interventions: a proposed framework for success.

Authors:  Gavin Yamey
Journal:  PLoS Med       Date:  2011-06-28       Impact factor: 11.069

4.  From DOTS to the Stop TB Strategy: DOTS coverage and trend of tuberculosis notification in Ebonyi, southeastern Nigeria, 1998-2009.

Authors:  Kingsley Ukwaja; Isaac Alobu; Ngozi Ifebunandu; Chijioke Osakwe; Chika Igwenyi
Journal:  Pan Afr Med J       Date:  2011-05-31

5.  Health Systems Readiness to Manage the Hypertension Epidemic in Primary Health Care Facilities in the Western Cape, South Africa: A Study Protocol.

Authors:  Rodrigue Innocent Deuboué Tchialeu; Sanni Yaya; Ronald Labonté
Journal:  JMIR Res Protoc       Date:  2016-02-29

Review 6.  Narrative review of models and success factors for scaling up public health interventions.

Authors:  Andrew J Milat; Adrian Bauman; Sally Redman
Journal:  Implement Sci       Date:  2015-08-12       Impact factor: 7.327

7.  Development of a brief instrument for assessing healthcare employee satisfaction in a low-income setting.

Authors:  Rachelle Alpern; Maureen E Canavan; Jennifer T Thompson; Zahirah McNatt; Dawit Tatek; Tessa Lindfield; Elizabeth H Bradley
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.